Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warning Letter Roundup & Recap – October 13, 2015

This article was originally published in The Gray Sheet

Executive Summary

An FDA investigator observed two different products with the same lot number at a manufacturer of cannulas and trocars; employees at Lusys Labs – a maker of in vitro diagnostic kits – handled and packaged coated membranes with bare hands; procedures at software-maker Merge Healthcare allowed for devices that hadn't fully completed design validation to be shipped to end users for clinical use on patients; and more. Six device warning letters were listed by FDA this week.

You may also be interested in...



Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment

Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.

UK’s NICE Goes Ahead With Parkinson’s Product Funding But Pending Real-World Data

Five remote monitoring medical devices that have “transformational” potential for Parkinson’s disease are to be conditionally funded via the UK’s National Health Service in a drive to address clinical and cost-effectiveness uncertainties using data from real patients.

Expert Panel View On First Ebola Test Submission: Reservations About Use In EU

The IVD expert panel has reviewed the performance of the 16th IVD that it has been asked to assess. The outcome is generally favorable – but with some reservations, including its use in the EU.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel